Company intelligence / Profile preview
Visirna Therapeutics
Shanghai, Shanghai, Chinavisirna.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
Visirna has multiple programs in late-stage clinical development, with Plozasiran at NDA/BLA stage, Zodasiran in Phase 3, VSA-006 in Phase 2, and VSA012 in Phase 1[4][9]
- Therapeutic areas
- GastroenterologyHematologyCardiovascularMetabolic Disorders
- Modalities
- siRNA (small interfering RNA)RNAi therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Arrowhead Pharmaceuticals
Beyond the preview
Go deeper on Visirna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Visirna Therapeutics.